News

Simon Crowe Set to Lead Finance as Arcadis’ New CFO

Simon Crowe Set to Lead Finance as Arcadis’ New CFO

Simon Crowe Set to Lead Finance as Arcadis’ New CFO

Arcadis, recognized as a global leader in sustainable design, engineering, and consultancy solutions, has made a significant executive appointment. The Supervisory Board has nominated Simon Crowe as the new Chief Financial Officer (CFO) and a member of the Executive Board. His appointment comes as the company navigates its future with a strong emphasis on strategic growth and operational excellence.

Simon Crowe's Professional Journey

Bringing over 30 years of diverse experience, Simon Crowe is set to succeed Virginie Duperat-Vergne. His extensive background spans across different regions including Europe, Asia, North America, and Africa. He is well-versed in leading high-performing finance teams in both NYSE-listed companies and private equity-backed settings.

Before joining Arcadis, Simon held the position of CFO at Wood Mackenzie, a notable firm specializing in data solutions for the energy and natural resources sectors. His expertise was pivotal in his previous role at ERM, where he played an instrumental part in transforming the organization, overseeing significant acquisitions, and facilitating its valued sale to KKR. His capabilities have consistently shown a commitment to driving financial performance and delivering long-term value.

Leadership Insights from Arcadis’ CEO

Alan Brookes, the CEO of Arcadis, expressed strong optimism about Simon’s appointment, stating, “Simon’s extensive experience and transparent leadership style make him an invaluable addition to our team. His insight into financial management and strategic growth will align perfectly with our ambitions for the future.”

The leadership team at Arcadis believes that Simon’s deep understanding of the consulting industry will support ongoing growth initiatives and enhance the company's financial strategies. His approach to fostering a culture of accountability and innovation is expected to contribute positively to the organization.

What’s Next for Simon Crowe?

Simon Crowe will officially join Arcadis as CFO Nominee on September 15, leading through an interim period until the extraordinary General Meeting, which is scheduled for September 30. This transitional phase will allow for a smooth induction into the executive team, ensuring that the finance function aligns seamlessly with the company's strategic goals.

Chief Executive Alan Brookes reiterated the importance of continuity during this transition, extending gratitude to Willem Baars for his leadership as interim CFO during this time. The commitment to a smooth leadership transition reflects Arcadis' dedication to its operational success and steadfast growth trajectory.

Appreciation from the Supervisory Board

Michiel Lap, Chairman of the Supervisory Board of Arcadis, also shared positive remarks about Simon’s nomination. The evaluation process that led to his selection was thorough, highlighting his extensive background in finance and corporate capital markets. This rigorous search reflects the Board’s commitment to nurturing long-term growth and stability within the organization.

Simon’s trajectory has been marked by significant achievements that underline his ability to enhance value creation through strategic finance and operational improvements.

About Arcadis

Arcadis stands at the forefront of innovative solutions for today’s pressing challenges. The firm’s global team of over 35,000 professionals is driven by sustainability, ingenuity, and technological advancement. Collaborating across sectors such as environment, energy, infrastructure, and water, Arcadis aims to co-create impactful solutions that contribute positively to communities worldwide.

In 2024, Arcadis reported impressive financial results, achieving substantial gross revenues. This growth trajectory is a testament to the company’s strategic initiatives and the effectiveness of its leadership team.

Contact Information

For any inquiries regarding this announcement, please reach out to the Arcadis Investor Relations team. Christine Disch is available via mobile at +31 6 15376020 or by email at christine.disch@arcadis.com. Chris Wiggan can be contacted at +44 7966 404889 or via email at chris.wiggan@arcadis.com.

Frequently Asked Questions

Who is Simon Crowe?

Simon Crowe is the newly nominated CFO of Arcadis, with extensive experience in finance across various regions and industries.

When is Simon Crowe joining Arcadis?

Simon Crowe will join Arcadis as CFO Nominee on September 15, leading to the General Meeting scheduled for September 30.

What are Simon Crowe's previous roles?

Prior to Arcadis, he served as CFO at Wood Mackenzie and ERM, contributing significantly to their financial transformations and growth.

What is Arcadis known for?

Arcadis is recognized for its sustainable design and consultancy solutions, helping clients tackle pressing global challenges across various sectors.

Who should I contact for more information?

You can contact Christine Disch or Chris Wiggan from Arcadis Investor Relations for further inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Can Take Charge in Outset Medical Securities Case

Updated Category News Views 226

Investors Can Take Control in Outset Medical Securities Case Investors seeking justice now have a valuable opportunity to take the lead in a class action lawsuit against Outset Medical, Inc. (NASDAQ: OM). This legal effort arises from claims suggesting that the company may not have been fully transparent about its product marketing and operational practices. Understanding...

Continue Reading
Understanding Market Dynamics for IDEXX Laboratories (IDXX)

Updated Category News Views 140

Insights into IDEXX Laboratories Option Trading In recent times, there has been a notable bearish sentiment among major investors regarding IDEXX Laboratories. Taking a closer look at the trading activities surrounding this stock, our attention shifts towards its options market dynamics. Recent Trading Patterns Analyzing the options history for IDEXX Laboratories (NASDAQ:...

Continue Reading
Upcoming Earnings Reports and Market Insights for Investors

Updated Category News Views 164

Key Companies Reporting Earnings Soon As investors gear up for a busy earnings week, a variety of companies are set to disclose their quarterly results. These reports often provide valuable insights into business performance and market trends. Companies Scheduled to Report Before Market Opens So-Young International Inc (NASDAQ: SY) So-Young is anticipated to announce its...

Continue Reading
Intelligent Alpha Launches Innovative AI-Driven ETF for Investors

Updated Category News Views 269

Welcome to Intelligent Alpha and AI-Driven Investments In today's fast-paced investment world, Doug Clinton, co-founder and Managing Partner at Deepwater Asset Management, has introduced Intelligent Alpha, a groundbreaking investment firm focused on utilizing the power of artificial intelligence. This unique firm distinguishes itself by having an investment committee that...

Continue Reading
Investors of Lineage, Inc. (LINE) Consider Class Action Suit

Updated Category News Views 141

Class Action Lawsuit Against Lineage, Inc. In the financial landscape, every investor hopes to see growth in their investments. However, recent developments with Lineage, Inc. have prompted concern among shareholders. It has come to light that some investors may have sustained losses due to alleged securities fraud surrounding the company's performance. As a result, legal...

Continue Reading